ResultsIQ

ResultsIQ › Latest results › Cohance Lifesciences Limited

Cohance Lifesciences Limited Q2 FY27 earnings call summary

NSE: COHANCE · BSE: 543064

Earnings call of 6 Nov 2026, summarised by AI from the filing.

H2 FY27 expected to deliver year-on-year growth in both revenue and EBITDA, despite the Suryapet closure order.

Key takeaways

  1. H2 guidance H2 FY27 expected to deliver year-on-year growth in both revenue and EBITDA, despite the Suryapet closure order.
  2. Specialty cut Specialty Chemicals FY27 outlook cut to a year-on-year revenue decline from the earlier expectation of broadly flat.
  3. New programmes Three lateral programmes from large global pharma, two commercial and one phase III, broaden the medium-term opportunity base.
  4. Suryapet risk Impact of the Suryapet closure order is still being assessed and not quantified.

Original filing on BSE

Cohance Lifesciences Limited Q2 FY27 results

As filed: Revenue ₹477 cr (−14% year on year), EBITDA ₹35.4 cr (−71% year on year), PAT ₹2.3 cr (−97% year on year), EBITDA margin 7.4% (−1,000 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹422 cr (−23% year on year), EBITDA ₹1.2 cr (−99% year on year), PAT −₹45.2 cr (−198% year on year), EBITDA margin 0.3% (−1,000 bps). Score 0 of 100, Below trend. EBITDA margin fell 1000 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 32% from last quarter. Share price after the results: +6.3% in 30 days (Nifty 500: −2.0%).
  • Q4 FY26: Revenue ₹619 cr (+54% year on year), EBITDA ₹98.7 cr (+33% year on year), PAT ₹8.3 cr (−30% year on year), EBITDA margin 15.9% (−247 bps). Score 55 of 100, In line with trend. EBITDA margin fell 247 bps year on year. Tax rate 58%. Not enough history for a trend yet: scored on growth alone. Profit fell 20% from last quarter. Share price after the results: −12.6% in 30 days (Nifty 500: −0.8%).
  • Q3 FY26: Revenue ₹482 cr, EBITDA ₹103 cr, PAT ₹47.3 cr, EBITDA margin 21.3%. Not scored. No result for the same quarter last year. Share price after the results: −15.6% in 29 days (Nifty 500: −9.6%).
  • H1 FY26: Revenue ₹981 cr, EBITDA ₹236 cr, PAT ₹147 cr, EBITDA margin 24.1%. Not scored. No result for the same half-year last year. Share price after the results: −22.3% in 30 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹484 cr, EBITDA ₹104 cr, PAT ₹53.0 cr, EBITDA margin 21.5%. Not scored. No result for the same quarter last year. Share price after the results: −0.6% in 30 days (Nifty 500: +2.2%).
  • Q4 FY25: Revenue ₹330 cr, EBITDA ₹66.0 cr, PAT ₹44.0 cr, EBITDA margin 20.0%. Not scored. No result for the same quarter last year. Share price after the results: −14.9% in 30 days (Nifty 500: +3.7%).

Past price moves after results do not indicate future moves. Not a recommendation.

Cohance Lifesciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.